Liver disease in women: The influence of gender on epidemiology, natural history, and patient outcomes

Gastroenterology and Hepatology

Volumn 9, Issue 10, 2013, Pages 633-639

  Guy, Jennifer ^a   Peters, Marion G ^b  

^a CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Epidemiology; Female; Gender; Liver disease; Sex

Indexed keywords

ACUTE LIVER FAILURE; ARTICLE; AUTOIMMUNE HEPATITIS; AUTOIMMUNE LIVER DISEASE; CHRONIC LIVER DISEASE; CLINICAL FEATURE; DISEASE COURSE; EPIDEMIOLOGICAL DATA; HEPATITIS C VIRUS; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER DISEASE; LIVER GRAFT; LIVER INJURY; LIVER TOXICITY; LIVER TRANSPLANTATION; LIVER TUMOR; MEDICAL HISTORY; NONALCOHOLIC FATTY LIVER; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PRIMARY BILIARY CIRRHOSIS; PRIMARY SCLEROSING CHOLANGITIS; SEX DIFFERENCE; SURVIVAL; TREATMENT OUTCOME; VIRUS HEPATITIS;

EID: 84887759285     PISSN: 15547914     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (83)

1. Becker U, Deis A, Sorensen TI, et al. Prediction of risk of liver disease by alcohol intake, sex, and age: a prospective population study. Hepatology. 1996;23(5):1025-1029. (Pubitemid 26137041)
2. Lee WM, Squires RH Jr, Nyberg SL, Doo E, Hoofnagle JH. Acute liver failure: summary of a workshop. Hepatology. 2008;47(4):1401-1415. (Pubitemid 351547926)
3. Reuben A, Koch DG, Lee WM. Drug-induced acute liver failure: results of a U.S. multicenter, prospective study. Hepatology. 2010;52(6):2065-2076.
4. Jepsen P, Ott P, Andersen PK, Sorensen HT, Vilstrup H. Risk for hepatocellular carcinoma in patients with alcoholic cirrhosis: a Danish nationwide cohort study. Ann Intern Med. 2012;156(12):841-847, W295.
5. Pares A, Caballeria J, Bruguera M, Torres M, Rodes J. Histological course of alcoholic hepatitis. Influence of abstinence, sex and extent of hepatic damage. J Hepatol. 1986;2(1):33-42. (Pubitemid 16177384)
6. Poynard T, Mathurin P, Lai CL, et al. A comparison of fibrosis progression in chronic liver diseases. J Hepatol. 2003;38(3):257-265. (Pubitemid 36286537)
7. Trembling PM, Apostolidou S, Parkes J, et al. Influence of BMI and alcohol on liver-related morbidity and mortality in a cohort of 108,000 women from the general population from UKCTOCS. Gut. 2013;62:A3.
8. Thun MJ, Peto R, Lopez AD, et al. Alcohol consumption and mortality among middle-aged and elderly U.S. adults. N Engl J Med. 1997;337(24):1705-1714. (Pubitemid 27527766)
9. Thurman RG. Alcoholic liver injury involves activation of Kupffer cells by endotoxin. Am J Physiol. 1998;275(4 pt 1):G605-G611.
10. Ikejima K, Enomoto N, Iimuro Y, et al. Estrogen increases sensitivity of hepatic Kupffer cells to endotoxin. Am J Physiol. 1998;274(4 pt 1):G669-G676.
11. Colantoni A, Emanuele MA, Kovacs EJ, Villa E, Van Thiel DH. Hepatic estrogen receptors and alcohol intake. Mol Cell Endocrinol. 2002;193(1-2):101- 104. (Pubitemid 34823613)
12. Jarvelainen HA, Lukkari TA, Heinaro S, Sippel H, Lindros KO. The antiestrogen toremifene protects against alcoholic liver injury in female rats. J Hepatol. 2001;35(1):46-52. (Pubitemid 32646223)
13. Eagon PK. Alcoholic liver injury: influence of gender and hormones. World J Gastroenterol. 2010;16(11):1377-1384.
14. Waxman DJ, Holloway MG. Sex differences in the expression of hepatic drug metabolizing enzymes. Mol Pharmacol. 2009;76(2):215-228.
15. Wolbold R, Klein K, Burk O, et al. Sex is a major determinant of CYP3A4 expression in human liver. Hepatology. 2003;38(4):978-988. (Pubitemid 37221681)
16. Parikh-Patel A, Gold EB, Worman H, Krivy KE, Gershwin ME. Risk factors for primary biliary cirrhosis in a cohort of patients from the United States. Hepatology. 2001;33(1):16-21. (Pubitemid 32016882)
17. Manns MP, Czaja AJ, Gorham JD, et al. Diagnosis and management of autoimmune hepatitis. Hepatology. 2010;51(6):2193-2213.
18. Whitacre CC. Sex differences in autoimmune disease. Nat Immunol. 2001;2(9):777-780.
19. Donaldson PT. Genetics of liver disease: immunogenetics and disease pathogenesis. Gut. 2004;53(4):599-608. (Pubitemid 38372988)
20. Invernizzi P, Miozzo M, Battezzati PM, et al. Frequency of monosomy X in women with primary biliary cirrhosis. Lancet. 2004;363(9408):533-535. (Pubitemid 38229455)
21. Miozzo M, Selmi C, Gentilin B, et al. Preferential X chromosome loss but random inactivation characterize primary biliary cirrhosis. Hepatology. 2007;46(2):456-462. (Pubitemid 47344781)
22. Corpechot C, Chretien Y, Chazouilleres O, Poupon R. Demographic, lifestyle, medical and familial factors associated with primary biliary cirrhosis. J Hepatol. 2010;53(1):162-169.
23. Gershwin ME, Selmi C, Worman HJ, et al. Risk factors and comorbidities in primary biliary cirrhosis: a controlled interview-based study of 1032 patients. Hepatology. 2005;42(5):1194-1202. (Pubitemid 43112687)
24. Prince MI, Ducker SJ, James OF. Case-control studies of risk factors for primary biliary cirrhosis in two United Kingdom populations. Gut. 2010;59(4):508-512.
25. Prince M, Chetwynd A, Newman W, Metcalf JV, James OF. Survival and symptom progression in a geographically based cohort of patients with primary biliary cirrhosis: follow-up for up to 28 years. Gastroenterology. 2002;123(4):1044-1051.
26. Smyk DS, Rigopoulou EI, Pares A, et al. Sex differences associated with primary biliary cirrhosis. Clin Dev Immunol. 2012;2012:610504.
27. Czaja AJ, Donaldson PT. Gender effects and synergisms with histocompatibility leukocyte antigens in type 1 autoimmune hepatitis. Am J Gastroenterol. 2002;97(8):2051-2057.
28. Bambha K, Kim WR, Talwalkar J, et al. Incidence, clinical spectrum, and outcomes of primary sclerosing cholangitis in a United States community. Gastroenterology. 2003;125(5):1364-1369. (Pubitemid 37409756)
29. Singh S, Talwalkar JA. Primary sclerosing cholangitis: diagnosis, prognosis, and management. Clin Gastroenterol Hepatol. 2013;11(8):898-907.
30. Tischendorf JJ, Hecker H, Kruger M, Manns MP, Meier PN. Characterization, outcome, and prognosis in 273 patients with primary sclerosing cholangitis: a single center study. Am J Gastroenterol. 2007;102(1):107-114. (Pubitemid 46072050)
31. Boonstra K, Weersma RK, van Erpecum KJ, et al. Population-based epidemiology, malignancy risk and outcome of primary sclerosing cholangitis [published online June 14, 2013]. Hepatology. doi: 10.1002/hep.26565.
32. Wiesner RH, Grambsch PM, Dickson ER, et al. Primary sclerosing cholangitis: natural history, prognostic factors and survival analysis. Hepatology. 1989;10(4):430-436. (Pubitemid 19255462)
33. Gandolfi L, Leo P, Solmi L, Vitelli E, Verros G, Colecchia A. Natural history of hepatic haemangiomas: clinical and ultrasound study. Gut. 1991;32(6):677-680.
34. Carrim ZI, Murchison JT. The prevalence of simple renal and hepatic cysts detected by spiral computed tomography. Clin Radiol. 2003;58(8):626-629. (Pubitemid 37121138)
35. Devaney K, Goodman ZD, Ishak KG. Hepatobiliary cystadenoma and cystadenocarcinoma. A light microscopic and immunohistochemical study of 70 patients. Am J Surg Pathol. 1994;18(11):1078-1091. (Pubitemid 24337615)
36. Nault JC, Bioulac-Sage P, Zucman-Rossi J. Hepatocellular benign tumors- from molecular classification to personalized clinical care. Gastroenterology. 2013;144(5):888-902.
37. Balabaud C, Al-Rabih WR, Chen PJ, et al. Focal nodular hyperplasia and hepatocellular adenoma around the world viewed through the scope of the immunopathological classification. Int J Hepatol. 2013;2013:268625.
38. Trotter JF, Everson GT. Benign focal lesions of the liver. Clin Liver Dis. 2001;5(1):17-42, v. (Pubitemid 32118637)
39. Scalori A, Tavani A, Gallus S, La Vecchia C, Colombo M. Oral contraceptives and the risk of focal nodular hyperplasia of the liver: a case-control study. Am J Obstet Gynecol. 2002;186(2):195-197. (Pubitemid 34165432)
40. Mathieu D, Kobeiter H, Maison P, et al. Oral contraceptive use and focal nodular hyperplasia of the liver. Gastroenterology. 2000;118(3):560-564. (Pubitemid 30140854)
41. Glinkova V, Shevah O, Boaz M, Levine A, Shirin H. Hepatic haemangiomas: possible association with female sex hormones. Gut. 2004;53(9):1352-1355. (Pubitemid 39120126)
42. Rebouissou S, Bioulac-Sage P, Zucman-Rossi J. Molecular pathogenesis of focal nodular hyperplasia and hepatocellular adenoma. J Hepatol. 2008;48(1):163-170. (Pubitemid 350199576)
43. El-Serag HB, Davila JA, Petersen NJ, McGlynn KA. The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med. 2003;139(10):817-823.
44. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet. 2012;379(9822):1245-1255.
45. Wong R, Corley DA. Racial and ethnic variations in hepatocellular carcinoma incidence within the United States. Am J Med. 2008;121(6):525-531. (Pubitemid 351694349)
46. El-Serag HB, Mason AC, Key C. Trends in survival of patients with hepatocellular carcinoma between 1977 and 1996 in the United States. Hepatology. 2001;33(1):62-65. (Pubitemid 32016888)
47. Wong RJ, Corley DA. Survival differences by race/ethnicity and treatment for localized hepatocellular carcinoma within the United States. Dig Dis Sci. 2009;54(9):2031-2039.
48. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53(3):1020-1022.
49. Matsumoto T, Takagi H, Mori M. Androgen dependency of hepatocarcinogenesis in TGF-alpha transgenic mice. Liver. 2000;20(3):228-233. (Pubitemid 30342721)
50. Tanaka K, Sakai H, Hashizume M, Hirohata T. Serum testosterone:estradiol ratio and the development of hepatocellular carcinoma among male cirrhotic patients. Cancer Res. 2000;60(18):5106-5110.
51. Naugler WE, Sakurai T, Kim S, et al. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science. 2007;317(5834):121-124. (Pubitemid 47056470)
52. Adams LA, Lymp JF, St Sauver J, et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology. 2005;129(1):113-121. (Pubitemid 41002048)
53. Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther. 2011;34(3):274-285.
54. Lazo M, Clark JM. The epidemiology of nonalcoholic fatty liver disease: a global perspective. Semin Liver Dis. 2008;28(4):339-350.
55. Gutierrez-Grobe Y, Ponciano-Rodriguez G, Ramos MH, Uribe M, Mendez- Sanchez N. Prevalence of nonalcoholic fatty liver disease in premenopausal, posmenopausal and polycystic ovary syndrome women. The role of estrogens. Ann Hepatol. 2010;9(4):402-409.
56. Liu SH, Lazo M, Koteish A, et al. Oral contraceptive pill use is associated with reduced odds of nonalcoholic fatty liver disease in menstruating women: results from NHANES III [published online Nov 28, 2012]. J Gastroenterol. doi: 10.1007/s00535-012-0715-8.
57. Neuschwander-Tetri BA, Clark JM, Bass NM, et al. Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease. Hepatology. 2010;52(3):913-924.
58. Kenny-Walsh E. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group. N Engl J Med. 1999;340(16):1228-1233. (Pubitemid 29181642)
59. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet. 1997;349(9055):825-832. (Pubitemid 27129209)
60. Levine RA, Sanderson SO, Ploutz-Snyder R, et al. Assessment of fibrosis progression in untreated irish women with chronic hepatitis C contracted from immunoglobulin anti-D. Clin Gastroenterol Hepatol. 2006;4(10):1271-1277. (Pubitemid 44512210)
61. Codes L, Asselah T, Cazals-Hatem D, et al. Liver fibrosis in women with chronic hepatitis C: evidence for the negative role of menopause and steatosis and the potential benefit of hormone replacement therapy. Gut. 2007;56(3):390-395. (Pubitemid 46579771)
62. Bissell DM. Sex and hepatic fibrosis. Hepatology. 1999;29(3):988-989. (Pubitemid 29109620)
63. Yasuda M, Shimizu I, Shiba M, Ito S. Suppressive effects of estradiol on dimethylnitrosamine- induced fibrosis of the liver in rats. Hepatology. 1999;29(3):719-727. (Pubitemid 29109585)
64. McHutchison JG, Lawitz EJ, Shiffman ML, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med. 2009;361(6):580-593.
65. Conjeevaram HS, Fried MW, Jeffers LJ, et al. Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology. 2006;131(2):470-477. (Pubitemid 44142464)
66. Villa E, Vukotic R, Camma C, et al. Reproductive status is associated with the severity of fibrosis in women with hepatitis C. PLoS One. 2012;7(9):e44624.
67. Liaw YF, Brunetto MR, Hadziyannis S. The natural history of chronic HBV infection and geographical differences. Antivir Ther. 2010;15(suppl 3):25-33.
68. Litwin T, Gromadzka G, Czlonkowska A. Gender differences in Wilson's disease. J Neurol Sci. 2012;312(1-2):31-35.
69. Bacon BR, Adams PC, Kowdley KV, Powell LW, Tavill AS; American Association for the Study of Liver Diseases. Diagnosis and management of hemochromatosis: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology. 2011;54(1):328-343.
70. Adams PC, Reboussin DM, Barton JC, et al. Hemochromatosis and iron-overload screening in a racially diverse population. N Engl J Med. 2005;352(17):1769-1778. (Pubitemid 40570925)
71. Allen KJ, Gurrin LC, Constantine CC, et al. Iron-overload-related disease in HFE hereditary hemochromatosis. N Engl J Med. 2008;358(3):221-230.
72. Harrison-Findik DD. Gender-related variations in iron metabolism and liver diseases. World J Hepatol. 2010;2(8):302-310.
73. Rogers RG, Everett BG, Saint Onge JM, Krueger PM. Social, behavioral, and biological factors, and sex differences in mortality. Demography. 2010;47(3):555-578.
74. Burra P, De Martin E, Gitto S, Villa E. Influence of age and gender before and after liver transplantation. Liver Transpl. 2013;19(2):122-134.
75. Moylan CA, Brady CW, Johnson JL, Smith AD, Tuttle-Newhall JE, Muir AJ. Disparities in liver transplantation before and after introduction of the MELD score. JAMA. 2008;300(20):2371-2378.
76. Mathur AK, Schaubel DE, Gong Q, Guidinger MK, Merion RM. Sexbased disparities in liver transplant rates in the United States. Am J Transplant. 2011;11(7):1435-1443.
77. Fink MA, Berry SR, Gow PJ, et al. Risk factors for liver transplantation waiting list mortality. J Gastroenterol Hepatol. 2007;22(1):119-124. (Pubitemid 44953426)
78. Lai JC, Terrault NA, Vittinghoff E, Biggins SW. Height contributes to the gender difference in wait-list mortality under the MELD-based liver allocation system. Am J Transpl. 2010;10(12):2658-2664.
79. Waki K. UNOS Liver Registry: ten year survivals. Clin Transpl. 2006:29-39.
80. Thomas DL, Astemborski J, Rai RM, et al. The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA. 2000;284(4):450-456. (Pubitemid 30484478)
81. Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology. 2002;122(4):889-896. (Pubitemid 34267271)
82. Lai JC, Verna EC, Brown RS Jr, et al. Hepatitis C virus-infected women have a higher risk of advanced fibrosis and graft loss after liver transplantation than men. Hepatology. 2011;54(2):418-424.
83. Thuluvath PJ, Guidinger MK, Fung JJ, Johnson LB, Rayhill SC, Pelletier SJ. Liver transplantation in the United States, 1999-2008. Am J Transpl. 2010; 10(4 pt 2):1003-1019.